Market Cap 17.16M
Revenue (ttm) 0.00
Net Income (ttm) -60.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,958,500
Avg Vol 810,258
Day's Range N/A - N/A
Shares Out 48.60M
Stochastic %K 7%
Beta 0.30
Analysts Strong Sell
Price Target $6.00

Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 952 0555
Address:
200 Talcott Ave, 2nd Floor, Watertown, United States
skyrockets_Inc
skyrockets_Inc Aug. 3 at 2:51 PM
$HOWL Friday was a free gift for those adding today. Smart money knows this is going back up.
0 · Reply
Chartwatcher1
Chartwatcher1 Aug. 3 at 2:00 PM
$HOWL adding here .379
0 · Reply
SGWibss
SGWibss Aug. 3 at 12:34 PM
$HOWL lets have a good week
0 · Reply
SwingTrades1
SwingTrades1 Aug. 3 at 2:52 AM
$HOWL Easy to overlook because it's from 2024, but it fits today's sequence remarkably well. Jazz may have closed one chapter, not the entire story. The remaining platform is where the real strategic value could lie. Do your own due diligence....https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/a03312024ex991.htm
0 · Reply
BiotechValues
BiotechValues Aug. 1 at 10:33 PM
$HOWL AI believes this level of spend is rather high and potentially signals positive signs behind the scenes:
0 · Reply
zawojak
zawojak Aug. 1 at 11:28 AM
$HOWL idk what they said on the teleconference but it made price tank 30% ...at this point it's POS smh
0 · Reply
SwingTrades1
SwingTrades1 Aug. 1 at 3:20 AM
$HOWL 1. Jazz validated an INDUKINE-derived asset (JZP898/WTX-613) 2. WTX-124 and WTX-330 are the larger oncology opportunities 3. The company has already moved toward strategic alternatives with Piper Sandler 4. The next data update is the value inflection point Here is the dot: 1 stone and 2 kills https://www.fiercebiotech.com/biotech/vertexs-latest-autoimmune-tce-play-involves-28m-upfront-abcellera
0 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 1 at 12:23 AM
$HOWL The writing is on the wall (see image below). What company do you know that is in 'strategic alternatives' but still burns 1.1m a quarter on their Pre-clinical unnamed candidates (i.e. the INDUCER pipeline) ? THE ANSWER IS: a company that is planning on selling those pre-clinical assets in the near future. The theory is as follows: --> asset sales first on pre-clinical INDUCER programs to improve cash position --> continue WTX-124 and WTX-330 trials until final data release (as stated in PR today) --> if data is good, asset sales of WTX-124, 330, and potentially other INDUKINE assets --> final step.. RM the remaining cash and shell, possibly return excess cash to shareholders as a dividend
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 31 at 6:42 PM
$HOWL Dang....my account is back to where it was only 6 days ago. Perhaps I should panic and sell out completely now 🤣
0 · Reply
BiotechValues
BiotechValues Jul. 31 at 5:27 PM
$HOWL definitely some major things going on behind the scenes given they dropped $3.5M in q2 alone, on legal counsel and advisors for the SA process. That number was only $0.5M in q1
1 · Reply
Latest News on HOWL
Werewolf Therapeutics Quarterly report: Q2 2026

Jul 31, 2026, 7:00 AM EDT - 3 days ago

Werewolf Therapeutics Quarterly report: Q2 2026


Werewolf Therapeutics Earnings release: Q2 2026

Jul 31, 2026, 7:00 AM EDT - 3 days ago

Werewolf Therapeutics Earnings release: Q2 2026


Werewolf Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Werewolf Therapeutics Quarterly report: Q1 2026


Werewolf Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Werewolf Therapeutics Earnings release: Q1 2026


Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c)

2026-03-27T11:15:46.000Z - 4 months ago

Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c)


Werewolf Therapeutics Annual report: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 4 months ago

Werewolf Therapeutics Annual report: Q4 2025


Werewolf Therapeutics Earnings release: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 4 months ago

Werewolf Therapeutics Earnings release: Q4 2025


Werewolf Therapeutics to explore strategic alternatives

2026-02-25T00:40:12.000Z - 5 months ago

Werewolf Therapeutics to explore strategic alternatives


Werewolf Therapeutics trading resumes

2026-02-24T21:51:46.000Z - 5 months ago

Werewolf Therapeutics trading resumes


Werewolf Therapeutics trading halted, news pending

2026-02-24T21:10:20.000Z - 5 months ago

Werewolf Therapeutics trading halted, news pending


Werewolf Therapeutics announces 64% workforce reduction

2026-02-13T21:30:19.000Z - 6 months ago

Werewolf Therapeutics announces 64% workforce reduction


Citizens downgrades Werewolf Therapeutics on need for capital

2025-12-19T15:35:48.000Z - 8 months ago

Citizens downgrades Werewolf Therapeutics on need for capital


Werewolf Therapeutics announces 2025 priorities

2025-12-18T13:20:21.000Z - 8 months ago

Werewolf Therapeutics announces 2025 priorities


Werewolf Therapeutics Announces Pipeline and Business Updates

Dec 18, 2025, 8:00 AM EST - 8 months ago

Werewolf Therapeutics Announces Pipeline and Business Updates


Werewolf Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 9 months ago

Werewolf Therapeutics Earnings release: Q3 2025


Werewolf Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 9 months ago

Werewolf Therapeutics Quarterly report: Q3 2025


Werewolf Therapeutics reports Q3 EPS (36c), consensus (38c)

2025-11-04T12:16:23.000Z - 9 months ago

Werewolf Therapeutics reports Q3 EPS (36c), consensus (38c)


Werewolf Therapeutics receives FTD from U.S. FDA for WTX-124

2025-10-08T12:06:01.000Z - 10 months ago

Werewolf Therapeutics receives FTD from U.S. FDA for WTX-124


Werewolf Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Earnings release: Q2 2025


Werewolf Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Quarterly report: Q2 2025


Werewolf Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Earnings release: Q1 2025


Werewolf Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Quarterly report: Q1 2025


Werewolf Therapeutics Slides: Corporate Presentation

May 8, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Slides: Corporate Presentation


Werewolf Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Proxy statement: Proxy Filing


Werewolf Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Proxy statement: Proxy Filing


Werewolf Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Earnings release: Q4 2024


Werewolf Therapeutics Annual report: Q4 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Annual report: Q4 2024


Werewolf Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 11:00 AM EST - 1 year ago

Werewolf Therapeutics Quarterly report: Q3 2024


Werewolf Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 11:00 AM EST - 1 year ago

Werewolf Therapeutics Earnings release: Q3 2024


Werewolf Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 11:00 AM EDT - 2 years ago

Werewolf Therapeutics Quarterly report: Q2 2024


Werewolf Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 11:00 AM EDT - 2 years ago

Werewolf Therapeutics Earnings release: Q2 2024


Werewolf Therapeutics Transcript: Study Update

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Transcript: Study Update


Werewolf Therapeutics Slides: Study Update

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Slides: Study Update


Werewolf Therapeutics Quarterly report: Q1 2024

May 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Quarterly report: Q1 2024


Werewolf Therapeutics Earnings release: Q1 2024

May 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Earnings release: Q1 2024


Werewolf Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Proxy statement: Proxy Filing


Werewolf Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Proxy statement: Proxy Filing


Werewolf Therapeutics Annual report: Q4 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Werewolf Therapeutics Annual report: Q4 2023


Werewolf Therapeutics Earnings release: Q4 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Werewolf Therapeutics Earnings release: Q4 2023


Werewolf Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 8:00 AM EST - 2 years ago

Werewolf Therapeutics Quarterly report: Q3 2023


Werewolf Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 8:00 AM EST - 2 years ago

Werewolf Therapeutics Earnings release: Q3 2023


Werewolf Therapeutics Slides: Investor Presentation

Nov 3, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics Slides: Investor Presentation


Werewolf Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Werewolf Therapeutics Quarterly report: Q2 2023


Werewolf Therapeutics Earnings release: Q2 2023

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Werewolf Therapeutics Earnings release: Q2 2023


skyrockets_Inc
skyrockets_Inc Aug. 3 at 2:51 PM
$HOWL Friday was a free gift for those adding today. Smart money knows this is going back up.
0 · Reply
Chartwatcher1
Chartwatcher1 Aug. 3 at 2:00 PM
$HOWL adding here .379
0 · Reply
SGWibss
SGWibss Aug. 3 at 12:34 PM
$HOWL lets have a good week
0 · Reply
SwingTrades1
SwingTrades1 Aug. 3 at 2:52 AM
$HOWL Easy to overlook because it's from 2024, but it fits today's sequence remarkably well. Jazz may have closed one chapter, not the entire story. The remaining platform is where the real strategic value could lie. Do your own due diligence....https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/a03312024ex991.htm
0 · Reply
BiotechValues
BiotechValues Aug. 1 at 10:33 PM
$HOWL AI believes this level of spend is rather high and potentially signals positive signs behind the scenes:
0 · Reply
zawojak
zawojak Aug. 1 at 11:28 AM
$HOWL idk what they said on the teleconference but it made price tank 30% ...at this point it's POS smh
0 · Reply
SwingTrades1
SwingTrades1 Aug. 1 at 3:20 AM
$HOWL 1. Jazz validated an INDUKINE-derived asset (JZP898/WTX-613) 2. WTX-124 and WTX-330 are the larger oncology opportunities 3. The company has already moved toward strategic alternatives with Piper Sandler 4. The next data update is the value inflection point Here is the dot: 1 stone and 2 kills https://www.fiercebiotech.com/biotech/vertexs-latest-autoimmune-tce-play-involves-28m-upfront-abcellera
0 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 1 at 12:23 AM
$HOWL The writing is on the wall (see image below). What company do you know that is in 'strategic alternatives' but still burns 1.1m a quarter on their Pre-clinical unnamed candidates (i.e. the INDUCER pipeline) ? THE ANSWER IS: a company that is planning on selling those pre-clinical assets in the near future. The theory is as follows: --> asset sales first on pre-clinical INDUCER programs to improve cash position --> continue WTX-124 and WTX-330 trials until final data release (as stated in PR today) --> if data is good, asset sales of WTX-124, 330, and potentially other INDUKINE assets --> final step.. RM the remaining cash and shell, possibly return excess cash to shareholders as a dividend
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 31 at 6:42 PM
$HOWL Dang....my account is back to where it was only 6 days ago. Perhaps I should panic and sell out completely now 🤣
0 · Reply
BiotechValues
BiotechValues Jul. 31 at 5:27 PM
$HOWL definitely some major things going on behind the scenes given they dropped $3.5M in q2 alone, on legal counsel and advisors for the SA process. That number was only $0.5M in q1
1 · Reply
LabPsycho
LabPsycho Jul. 31 at 4:13 PM
$HOWL @Biotech_Beast @BiotechValues @skyrockets_Inc All reasonable posts. My counter is this basically trading at rapidly dwindling cash is not a favorable risk/reward at this price. I stand by my guess that 24 cents is more reasonable (provided no negative news) and if it hits that in the next 3 months because longer than that you are looking at them having only ~15M cash + tax loss selling pressure, plus overall market unwinding, sell off accelerating. At 2.5X this market cap, XLO with ~5X more cash and partners looks a little safer by comparision but I am thinking most biotechs going to retrace, esp the many with spectacular gains the past year. On the other hand, market makers tend to keep dropping bids on weak biotechs day of and a few days after quarterly report, so there's that game going on I suspect. Good luck
1 · Reply
BiotechValues
BiotechValues Jul. 31 at 3:50 PM
$HOWL know what you own and what they are gonna sell this year:
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 31 at 3:25 PM
$HOWL I love the retail panic here, makes for cheaper shares. Nothing has changed here. If you believed in this yesterday then nothing has changed. 900k shares strong here and adding more on dips, not selling. OBJECTIVE Analysis through July 31, 2026 (i.e. today) Highlights: --> 22m cash June 30 + 2m payment owed from Jazz = 24m cash --> 8-9m cash burn rate in the current quarter Q3, we are one month in so burn of 3m so far --> 24m cash subtract 3m burn puts us at 21m cash as of TODAY JULY 31, 2026, or 0.43/share in cash value alone. Selling at 0.38/share makes NO SENSE. I'm buying. --> This analysis gives ZERO value to any of the remaining assets of the NASDAQ shell which is worth 7-10m on it's own. If you include the shell value then floor value of company currently assuming only the cash and shell is 21m+9m = 30m or 0.61/share --> Any asset sale or platform sale will add much more to this valuation likely pushing this well above $1/share Do your own DD but I'm buying and holding
1 · Reply
zoomlik
zoomlik Jul. 31 at 3:09 PM
$HOWL What is cash burn in Q3 and Q4 ?
2 · Reply
Biotech_Beast
Biotech_Beast Jul. 31 at 2:55 PM
$HOWL I'm holding this junk. Interesting that there is more data ahead for the IL-12, I think that is of interest when you consider what GILD might pay XLO to get its hands on a masked IL-12 and already paid upfront to XLO. I don't know what of value could come from another update on the IL-2. The market already panned that data. Maybe some data in other tumor types? I wasn't really aware that they were still dosing patients. If it is ongoing follow up from the IL-2 treated mono and combo melanoma patients, well regular IL-2 has great durability of CR for example. Maybe there could be something encouraging there.
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 31 at 2:54 PM
$HOWL Lmao nothing 'objectively negative' about it. Neutral if anything. You and your brother just love bashing each other's stocks....that's not the definition of 'objective analysis'. Tell me what was negative in this PR ? I'll be waiting. A normal update that everyone expected. Cash runway update and a blanket statement on 'strategic alternatives are continuing as planned'. Same update that every single other strat alt company does. Not sure what you were expecting in this ER exactly...... the real value here is the news drop of asset/platform sales that will follow. Especially since this ER was released 2 weeks earlier than ever before.
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Jul. 31 at 2:26 PM
$HOWL objectively horrible update today. Long road ahead and TCE platform likely not worth much e.g. $BCAB. Can see this heading back to mid 0.30s.
1 · Reply
OTW_Enterprises
OTW_Enterprises Jul. 31 at 1:32 PM
$HOWL 640k volume pre-market and no substantial price change?
1 · Reply
G3HOPEWELL
G3HOPEWELL Jul. 31 at 1:09 PM
$HOWL 🐂 Added
0 · Reply
BiotechValues
BiotechValues Jul. 31 at 1:01 PM
$HOWL remember what happened to $CBIO? Suddenly sold their pre-clinical programs for $60M and stock spiked like 500%. HOWL has their INDUCER TCE programs that are in a very hot space. No doubt someone will come in and buy the platform given the upside potential there. This is what got me interested in HOWL in first place. The language in the PR today suggests "updates" on SA are coming (plural)
0 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 31 at 1:01 PM
$HOWL The theory here is this is going to be a multi-step strategic alternative process , hence the second half of year comment. Probably will be an asset and/or platform sale first, then it sounds like data after, then depending on that data potential other asset sale, and then finally RM the cash and shell and/or give special dividends to shareholders. I was in CBIO years ago that exactly did this same process. The first asset sale was in May and a string of other things in between and then finally a dividend and RM in Dec....so I think the 'Second half ' verbiage is very purposefully done because of this.
0 · Reply
Flowjob
Flowjob Jul. 31 at 12:17 PM
$HOWL update due in the second half of the year likely means EOY imo. Not in Q3. Cant rule out a reverse split as its been under a dollar since November. GLTA
1 · Reply